ARQL News and Press, ArQule Inc. From 10/13/19

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

ArQule, Inc. (ARQL) is a clinical stage pharmaceutical company pursuing multiple programs in biomarker-defined oncology and rare disease indications. ARQL stock saw some action in the last session, trading over 3 times of average volume at a 6% increase from the previous close. We will see w...

ArQule, Inc. (Nasdaq: ARQL) today announced that it will be presenting research on the company’s pan-AKT inhibitor, miransertib (ARQ 092), in a poster presentation at the 2019 ASHG Annual Meeting being held from October 15 to October 19, 2019 in Houston, Texas. The presentation wil...

I usually have at least one development-stage biotech in my portfolio at any given time. But after an unusually disappointing stretch with that usually profitable insider investment theme over the past year, my portfolio became devoid of dev-stage biotech earlier in September. I have high ex...

MOSAIC trial represents the first registrational trial for Proteus Syndrome and PIK3CA-related overgrowth spectrum ArQule, Inc. (Nasdaq: ARQL), today announced that the first patient was dosed in the registrational MOSAIC ( M iransertib in O vergrowth S yndromes in A dults and C h...

ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the 2019 Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 2:25 p.m. ET at the InterConti...

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on Tuesday, Septemb...

ArQule (NASDAQ: ARQL ) initiated with Buy rating and $13 (63% upside) price target at H.C. Wainwright. More news on: ArQule, Inc., Esperion Therapeutics, Inc., Aurora Cannabis Inc., Healthcare stocks news, Stocks on the move, , Read more ...

A little clinical data can go a long way. Promising updates from two pipeline assets have catapulted shares of ArQule (NASDAQ: ARQL) 230% higher since the beginning of 2019. The company's market cap soared to $1.3 billion, which is pretty impressive considering it has rarely topped $400 mill...